Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.

Oncotarget - 24 Jan 2024

Lee Mark, Morris Luc Gt

Abstract excerpt

A subset of thyroid cancers present at advanced stage or with dedifferentiated histology and have limited response to standard therapy. Tumors harboring the BRAF V600E mutation may be treated with BRAF inhibitors; however, tumor response is often short lived due to multiple compensatory resistance mechanisms. One mode of resistance is the transition to an alternative cell state, which on rare occasions can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Mutation
Share to p120 GTPase Activating Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Neoplasms

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 38275291
DOI: 10.18632/oncotarget.28544
PMCID: PMC10812235

Genes

BRAF
MTOR
ARID2
JAK1
MET
NF2
NRAS
PBRM1
PIK3CA
RASA1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.PMID 38275291Read ↗

NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma.Semantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

Genetic alterations in anaplastic thyroid carcinoma and targeted therapies (Review)Semantic proximity Read ↗

The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.Semantic proximity Read ↗

Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.Semantic proximity Read ↗

Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment StrategySemantic proximity Read ↗

Recent advances in anaplastic thyroid cancer management.Semantic proximity Read ↗

BRAF mutations in thyroid cancer.Semantic proximity Read ↗

The Role of the Kinase Inhibitors in Thyroid CancersSemantic proximity Read ↗

Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.Semantic proximity Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.